Negligible Rebound in Myopia Progression Following Cessation of Treatment with 0.01% Atropine for 3 years: Year-4 Results from the CHAMP Phase 3 Clinical Trial

Key Points

• This research aims to assess the rebound effect on myopia progression after stopping 0.01% atropine treatment for three years.
• Conducted as part of the CHAMP clinical trial.
• Participants received 0.01% atropine for myopia control.
• Myopia progression was monitored for four years, including one year post-treatment.
• Minimal rebound in myopia progression observed after stopping treatment.
• Results demonstrate sustained efficacy of 0.01% atropine for myopia control over three years.

Abstract